MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity

Xu, Lei-Bo; Beckebaum, Susanne; Iacob, Speranta; Wu, Gang; Kaiser, Gernot M.; Radtke, Arnold; Liu, Chao; Kabar, Iyad; Schmidt, Hartmut; Zhang, Xiaoyong; Lu, Mengji; Cicinnati, Vito R.

doi:10.1016/j.jhep.2013.10.028

Cited by 146 publications

(113 citation statements)

References 32 publications

Supporting

Mentioning

110

Contrasting

Order By: Relevance

“…This miRNA inhibits cell proliferation through the inhibition of three proteins EZH2, c-myc and MCL-1 involved in apoptotic process. Once their control is lost, these induce cell proliferation and migration (Xu et al, 2014). Interestingly, serum miR-101 levels were found to have an inverse correlation with tissue levels.…”

Section: Mir-101mentioning

confidence: 98%

HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma

Bronte

Fanale

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Section: Mir-101mentioning

confidence: 98%

HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma

Bronte

Fanale

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…MiR-101 overexpression downregulates EZH2, repressing proliferation, invasion, colony formation and cell cycle progression in vitro, while suppresses tumorigenicity in vivo [97] . miR-101 is also able to increase sensitivity to doxorubicin or fluorouracil, improving the activity of chemotherapeutic drugs in liver cancer cells [97] .…”

Section: Suz12 Marchesi I Et Al Ezh2 Inhibitors In Cancer Therapymentioning

confidence: 99%

“…miR-101 is also able to increase sensitivity to doxorubicin or fluorouracil, improving the activity of chemotherapeutic drugs in liver cancer cells [97] . Remarkably, in hepatocellular carcinoma, treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA) promotes miR-101 expression reducing levels of EZH2, EED and H3K27me3.…”

Section: Suz12 Marchesi I Et Al Ezh2 Inhibitors In Cancer Therapymentioning

confidence: 99%

Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment

Marchesi

Bagella

2016

WJCO

View full text Add to dashboard Cite

Polycomb group proteins represent a global silencing system involved in development regulation. In specific, they regulate the transition from proliferation to differentiation, contributing to stem-cell maintenance and inhibiting an inappropriate activation of differentiation programs. Enhancer of Zeste Homolog 2 (EZH2) is the catalytic subunit of Polycomb repressive complex 2, which induces transcriptional inhibition through the tri-methylation of histone H3, an epigenetic change associated with gene silencing. EZH2 expression is high in precursor cells while its level decreases in differentiated cells. EZH2 is upregulated in various cancers with high levels associated with metastatic cancer and poor prognosis. Indeed, aberrant expression of EZH2 causes the inhibition of several tumor suppressors and differentiation genes, resulting in an uncontrolled proliferation and tumor formation. This editorial explores the role of Polycomb repressive complex 2 in cancer, focusing in particular on EZH2. The canonical function of EZH2 in gene silencing, the non-canonical activities as the methylation of other proteins and the role in gene transcriptional activation, were summarized. Moreover, mutations of EZH2, responsible for an increased methyltransferase activity in cancer, were recapitulated. Finally, various drugs able to inhibit EZH2 with different mechanism were described, specifically underscoring the effects in several cancers, in order to clarify the role of EZH2 and understand if EZH2 blockade could be a new strategy for developing specific therapies or a way to increase sensitivity of cancer cells to standard therapies.

show abstract

“…Methyltransferase zeste homolog 2 (EZH2), an enzyme that is highly expressed in HCCs, can promote the invasion and metastasis of HCC through epigenetic modifications and the silencing of a series of miRNAs, including miR-101 [34] . However, recent research discovered that miR-101 can also directly target EZH2 to repress proliferation, colony formation, cell cycle progression, invasion of HCC in all tested cell lines (HepG2, Hep3B, Huh7, PLC/PRF5, SNU182, HepaRG and BEL-7402) and to enhance the sensitivity of chemotherapy drugs such as doxorubicin [35] .…”

Section: Mir-101mentioning

confidence: 99%

Non-coding RNAs: New therapeutic targets and opportunities for hepatocellular carcinoma

Ning

et al. 2016

Adv Mod Oncol Res

View full text Add to dashboard Cite

Non-coding RNAs (ncRNA) are RNA molecules without protein coding functions owing to the lack of an open reading frame (ORF). Based on the length, ncRNAs can be divided into long and short ncRNAs; short ncRNAs include miRNAs and piRNAs. Hepatocellular carcinoma (HCC) is among the most frequent forms of cancer worldwide and its incidence is increasing rapidly. Studies have found that ncRNAs are likely to play a crucial role in a variety of biological processes including the pathogenesis and progression of HCC. In this review, we summarized the regulation mechanism and biological functions of ncRNAs in HCC with respect to its application in HCC diagnosis, therapy and prognosis.

show abstract

MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity

Cited by 146 publications

References 32 publications

HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma

HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma

Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment

Non-coding RNAs: New therapeutic targets and opportunities for hepatocellular carcinoma

Contact Info

Product

Resources

About